ANIDRACTIV® · Platform Live

Targeting
Cellular
Senescence.

A pioneering biotechnology platform engineered to act on the fundamental mechanisms of tissue aging. By reprogramming cellular pathways, ANIDRACTIV® induces deep molecular regeneration and restores structural integrity.

FIG. 01 — Platform Schema
v.2.4
Senescence LoadTreatment (T)T0T2
Tissue reprogramming profile● in vivo
TRL9
Technology Readiness
Completed
EU MD Registration
Class I
Medical Device
IT
R&D Site
Backed by · R&D Ecosystem
FINCALABRAENTOPAN - HIGRUBINO IPTERME SIBARITE S.P.A.
§ 01bThe Paradigm Shift

For decades, cellular senescence has been trapped between two extremes: superficial topicals or systemic pharmacology.

Tissue longevity and repair do not need the systemic risks of synthetic pharmacology. They require precision biophysical regulation that works in harmony with human cellular biology.

While pharmaceutical senolytics struggle with systemic toxicity and conventional topicals remain inert on the skin surface, ANIDRACTIV® establishes a new standard: targeted management of cellular senescence with zero systemic drug burden and validated tissue regeneration.

Scientific evolution of senescence management
1961
Cellular Biology

The Hayflick Limit

Hayflick and Moorhead demonstrate that human fibroblasts stop dividing after a finite number of replications. Senescence is identified as an intrinsic cellular state — but no therapeutic route exists.

— Milestones summarised from peer-reviewed literature on cellular senescence.

§ 02Mission & Values

A new frontier in biophysical regeneration,
countering cellular senescence to restore tissue integrity.

Company

Piemmeggi is an advanced biotechnology company dedicated to the discovery and development of innovative molecular complexes to counter cellular senescence. The primary focus, driven by the proprietary ANIDRACTIV® platform, is deep tissue regeneration and skin longevity.

Our goal is to address severe skin aging and loss of viscoelasticity, and to translate the platform into regenerative indications with high unmet clinical need — detailed in the development pipeline below.

  • Tissue reprogramming
    Reprogramming cellular pathways for deep molecular regeneration.
  • Anti-senescence
    Targeting the core mechanisms of cellular senescence in skin.
  • Scientific rigor
    From in silico computational chemistry to in vivo clinical evidence.
  • Structural integrity
    Restoring tissue viscoelasticity and structural integrity.
§ 03Team & Expertise

A collective of experts in molecular sciences and venture capital.

Founded on Paolo Piazzetta's vision in computational chemistry, Piemmeggi unites molecular scientists and venture builders.

We operate with institutional governance, scientific rigor and strict compliance with the European MDR framework.

Computational Chemistry
Molecular modeling and simulation of complex biological systems.
Molecular Sciences
Biochemistry, applied enzymology and formulation.
Venture Capital
Capital deployment and scaling of deep-tech technologies.
Regulatory & QA
MDR compliance — technical file and post-market surveillance.
§ 04Technology Pipeline

From computational chemistry
to clinical evidence.

The ANIDRACTIV® platform translates rigorous research models — from the in silico level to in vivo — into real and safe solutions for tissue reprogramming and skin longevity.

ProgramAssetIndicationTRLStatusReference
AND-01ANIDRACTIV® — Core PlatformTissue reprogramming · Skin longevityTRL9EU MD RegistrationCompleted
AND-02Severe Skin Aging ProgramLoss of viscoelasticityTRL8Real-Life Pre-Market TrialIn vivo evidence — ongoing
AND-03Scars & Stretch MarksScars, stretch marks, post-acneTRL8Pre-ClinicalIn silico/vitro/vivo
AND-04AI driven clinical diagnosisSaMDTRL 5IN PROGRESSModel Validation

Regenerative Medicine Development Pipeline

ANIDRACTIV® is being advanced across selected cutaneous indications with a structured preclinical and regulatory development framework.

Therapeutic AreaBiological TargetMechanism of ActionStageTRLEvidence
PsoriasisSenescent keratinocyte pathways / IL-17/IL-23 signallingModulates senescent cell signalling and reduces cutaneous inflammation.Preclinical DevelopmentTRL5in silico / in vitro
DermatitisEpidermal barrier integrity / chronic inflammationRestores barrier function and reduces inflammatory mediators.Preclinical DevelopmentTRL5in silico / in vitro
Cutaneous UlcersTissue remodelling / microvascular supportPromotes extracellular matrix reorganisation and angiogenic support.Discovery PhaseTRL5in silico
BurnsRe-epithelialisation / fibrotic scarringAccelerates keratinocyte migration and limits myofibroblast activation.Discovery PhaseTRL5in silico
Pipeline updated — TRL per EU classification.
§ 05Partners

An elite network of scientific and industrial partners.

Intellectual Property
Rubino IP
Scientific Training
Terme sibarite S.P.A.
Innovation Network
FINCALABRA
Open Innovation Hub
Entopan - HIG
§ 06Invest & Partner

Join the next chapter of biophysical tissue regeneration.

Past event · Milan, Italy

SMAU Milano · 3–4 November 2026 | STAND D11

PIEMMEGGI presented the ANIDRACTIV® platform to investors, clinical partners and industry stakeholders.

Request event follow-up
Investor Relations · Due Diligence

For investors & venture capital

Executive summary, IP portfolio, EU MDR regulatory roadmap and industrial scale-up plan for the ANIDRACTIV® platform.

Request due diligence dossier
Clinical Partnering · Licensing

For clinical & industrial partners

Co-development, licensing and clinical studies on ulcers, burns, psoriasis and dermatitis, plus SaMD collaborations.

Initiate scientific evaluation
§ 07Contacts

For scientific dialogue, partnership or due diligence.

Reach our R&D, regulatory and business development team. We respond to qualified inquiries within five business days.

Email
info@piemmeggi.it
Registered office
Via Coschi 11 — 88046 Lamezia Terme (CZ), Italy
LinkedIn
linkedin.com/company/piemmeggi